What are the combination treatment options for non–small cell lung cancer (NSCLC) in patients with vascular endothelial growth factor (VEGF) mutations?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

For patients with VEGF mutations, the following agents are used in combination with chemotherapy:

  • Bevacizumab (Avastin)
  • Ramucirumab (Cyramza)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!